Daniel R. Chevallard
CIK 1706176 · Chief Financial Officer · last filed 2026-03-30
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$87.2K
Companies
3
Total Filings
31
Lifetime Open-Market Net
$94.1K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LENZ | Chief Financial Officer | 12,886 | $6.77 | $87.2K | $164.3K | 5 | 2026-03-30 |
| Viracta Therapeutics, Inc. (VIRX) Delisted | CFO and COO | 102,306 | $0.01 | $1.0K | -$99.4K | 16 | 2024-03-13 |
| Regulus Therapeutics Inc. (RGLS) Delisted | Chief Financial Officer | 77,870 | $8.16 | $635.4K | $29.2K | 9 | 2019-07-02 |
Recent Filings · Page 4 of 4
31 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-05-12 | Regulus Therapeutics Inc. (RGLS) Delisted | Grant (A) | — | $0 | EDGAR |
Showing 31–31 of 31
Prev
Page 4 of 4
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.